Korea United Pharm Inc. (033270.KS)
KRW 18480.0
(-1.75%)
KRW 18480.0
(-1.75%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 40.33 Billion KRW | 33.14% |
| 2022 | 30.29 Billion KRW | -8.16% |
| 2021 | 32.99 Billion KRW | -8.02% |
| 2020 | 35.86 Billion KRW | 9.81% |
| 2019 | 32.66 Billion KRW | 14.46% |
| 2018 | 28.53 Billion KRW | 13.34% |
| 2017 | 25.17 Billion KRW | 18.67% |
| 2016 | 21.21 Billion KRW | -23.88% |
| 2015 | 27.87 Billion KRW | 12.53% |
| 2014 | 24.76 Billion KRW | 4.01% |
| 2013 | 23.81 Billion KRW | 2.51% |
| 2012 | 23.23 Billion KRW | -15.08% |
| 2011 | 27.35 Billion KRW | 42.48% |
| 2010 | 19.2 Billion KRW | -9.39% |
| 2009 | 21.19 Billion KRW | 6.42% |
| 2008 | 19.91 Billion KRW | 1.75% |
| 2007 | 19.57 Billion KRW | 5.84% |
| 2006 | 18.49 Billion KRW | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q1 | 31.32 Billion KRW | -22.35% |
| 2024 Q2 | 17.62 Billion KRW | -43.73% |
| 2023 Q4 | 40.33 Billion KRW | -6.09% |
| 2023 Q2 | 44.46 Billion KRW | 24.27% |
| 2023 FY | 40.33 Billion KRW | 33.14% |
| 2023 Q1 | 35.78 Billion KRW | 18.1% |
| 2023 Q3 | 42.95 Billion KRW | -3.39% |
| 2022 Q3 | 32.24 Billion KRW | -3.53% |
| 2022 Q1 | 33.08 Billion KRW | 0.28% |
| 2022 FY | 30.29 Billion KRW | -8.16% |
| 2022 Q2 | 33.42 Billion KRW | 1.02% |
| 2022 Q4 | 30.29 Billion KRW | -6.03% |
| 2021 Q4 | 32.99 Billion KRW | -0.44% |
| 2021 FY | 32.99 Billion KRW | -8.02% |
| 2021 Q1 | 36.01 Billion KRW | 0.42% |
| 2021 Q2 | 35.77 Billion KRW | -0.67% |
| 2021 Q3 | 33.13 Billion KRW | -7.38% |
| 2020 FY | 35.86 Billion KRW | 9.81% |
| 2020 Q1 | 32.62 Billion KRW | -0.11% |
| 2020 Q3 | 35.8 Billion KRW | -0.15% |
| 2020 Q4 | 35.86 Billion KRW | 0.17% |
| 2020 Q2 | 35.86 Billion KRW | 9.92% |
| 2019 Q4 | 32.66 Billion KRW | -2.85% |
| 2019 FY | 32.66 Billion KRW | 14.46% |
| 2019 Q1 | 29.06 Billion KRW | 1.84% |
| 2019 Q2 | 28.38 Billion KRW | -2.34% |
| 2019 Q3 | 33.62 Billion KRW | 18.47% |
| 2018 Q3 | 30.92 Billion KRW | -2.06% |
| 2018 Q1 | 25.32 Billion KRW | 0.57% |
| 2018 Q2 | 31.57 Billion KRW | 24.68% |
| 2018 FY | 28.53 Billion KRW | 13.34% |
| 2018 Q4 | 28.53 Billion KRW | -7.71% |
| 2017 Q1 | 18.72 Billion KRW | -11.76% |
| 2017 Q4 | 25.17 Billion KRW | 23.49% |
| 2017 Q3 | 20.38 Billion KRW | 18.42% |
| 2017 Q2 | 17.21 Billion KRW | -8.04% |
| 2017 FY | 25.17 Billion KRW | 18.67% |
| 2016 Q1 | 27.73 Billion KRW | 0.0% |
| 2016 Q4 | 21.21 Billion KRW | -18.65% |
| 2016 Q3 | 26.08 Billion KRW | -1.64% |
| 2016 Q2 | 26.51 Billion KRW | -4.38% |
| 2016 FY | 21.21 Billion KRW | -23.88% |
| 2015 Q2 | 23.57 Billion KRW | -3.34% |
| 2015 Q1 | 24.38 Billion KRW | -1.55% |
| 2015 Q3 | 23.64 Billion KRW | 0.3% |
| 2015 FY | 27.87 Billion KRW | 12.53% |
| 2014 Q1 | 28.36 Billion KRW | 19.13% |
| 2014 Q2 | 28.13 Billion KRW | -0.81% |
| 2014 FY | 24.76 Billion KRW | 4.01% |
| 2014 Q4 | 24.76 Billion KRW | -11.45% |
| 2014 Q3 | 27.97 Billion KRW | -0.59% |
| 2013 FY | 23.81 Billion KRW | 2.51% |
| 2013 Q2 | 31.34 Billion KRW | 31.78% |
| 2013 Q1 | 23.78 Billion KRW | 2.38% |
| 2013 Q4 | 23.81 Billion KRW | 1.69% |
| 2013 Q3 | 23.41 Billion KRW | -25.28% |
| 2012 Q4 | 23.23 Billion KRW | 0.0% |
| 2012 FY | 23.23 Billion KRW | -15.08% |
| 2012 Q1 | 19.49 Billion KRW | 0.0% |
| 2011 Q1 | 28.81 Billion KRW | 50.06% |
| 2011 Q2 | 28.78 Billion KRW | -0.12% |
| 2011 Q3 | 25.75 Billion KRW | -10.5% |
| 2011 FY | 27.35 Billion KRW | 42.48% |
| 2010 Q4 | 19.2 Billion KRW | 3.15% |
| 2010 Q1 | 20.51 Billion KRW | -3.21% |
| 2010 FY | 19.2 Billion KRW | -9.39% |
| 2010 Q2 | 20.43 Billion KRW | -0.38% |
| 2010 Q3 | 18.61 Billion KRW | -8.91% |
| 2009 Q3 | 23.47 Billion KRW | 1.38% |
| 2009 Q4 | 21.19 Billion KRW | -9.74% |
| 2009 Q2 | 23.15 Billion KRW | 7.92% |
| 2009 Q1 | 21.45 Billion KRW | 7.77% |
| 2009 FY | 21.19 Billion KRW | 6.42% |
| 2008 Q2 | 21.4 Billion KRW | -2.28% |
| 2008 Q3 | 22.15 Billion KRW | 3.48% |
| 2008 Q1 | 21.9 Billion KRW | 0.0% |
| 2008 FY | 19.91 Billion KRW | 1.75% |
| 2008 Q4 | 19.91 Billion KRW | -10.1% |
| 2007 Q2 | 21.63 Billion KRW | 0.0% |
| 2007 Q3 | 20.57 Billion KRW | -4.91% |
| 2007 FY | 19.57 Billion KRW | 5.84% |
| 2006 FY | 18.49 Billion KRW | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 39.4 Billion KRW | -2.365% |
| Dong-A Socio Holdings Co., Ltd. | 691.88 Billion KRW | 94.17% |
| Ildong Holdings Co., Ltd. | 382.06 Billion KRW | 89.442% |
| HANDOK Inc. | 300.01 Billion KRW | 86.554% |
| Kukje Pharma Co., Ltd. | 30.66 Billion KRW | -31.56% |
| Yuhan Corporation | 230.07 Billion KRW | 82.467% |
| Dong-A ST Co., Ltd. | 406.7 Billion KRW | 90.082% |
| SAMSUNG PHARM. Co., LTD. | 595.48 Million KRW | -6674.139% |
| Hanmi Pharm. Co., Ltd. | 572.86 Billion KRW | 92.958% |
| Hanall Biopharma Co.,Ltd | 1.29 Billion KRW | -3025.773% |
| Ilyang Pharmaceutical Co.,Ltd | 85.15 Billion KRW | 52.631% |
| Dong Sung Bio Pharm.Co.,Ltd. | 43.27 Billion KRW | 6.78% |
| MYUNGMOON Pharm co.,Ltd | 90.48 Billion KRW | 55.418% |
| Hana Pharm Co., Ltd. | 26.53 Billion KRW | -52.033% |
| Yuyu Pharma, Inc. | 39.4 Billion KRW | -2.365% |
| Ilsung Pharmaceuticals Co., Ltd. | 238.12 Million KRW | -16840.206% |
| REYON Pharmaceutical Co., Ltd. | 225.05 Billion KRW | 82.076% |
| Aprogen pharmaceuticals,Inc. | 180.99 Billion KRW | 77.713% |
| JW Holdings Corporation | 554.58 Billion KRW | 92.726% |
| Ildong Pharmaceutical Co., Ltd. | 217.84 Billion KRW | 81.482% |
| Chong Kun Dang Pharmaceutical Corp. | 219.76 Billion KRW | 81.644% |
| JW Pharmaceutical Corporation | 170.28 Billion KRW | 76.31% |
| Shin Poong Pharm.Co.,Ltd. | 46.15 Billion KRW | 12.594% |
| Hyundai Pharmaceutical Co., Ltd. | 39.2 Billion KRW | -2.893% |
| Samil Pharmaceutical Co.,Ltd | 175.87 Billion KRW | 77.064% |
| Jeil Pharmaceutical Co.,Ltd | 84.96 Billion KRW | 52.523% |
| Yuyu Pharma, Inc. | 39.4 Billion KRW | -2.365% |
| Kwang Dong Pharmaceutical Co., Ltd. | 235.64 Billion KRW | 82.881% |
| Daewoong pharmaceutical Co.,Ltd | 469.68 Billion KRW | 91.411% |
| JW Pharmaceutical Corporation | 170.28 Billion KRW | 76.31% |
| Yuhan Corporation | 230.07 Billion KRW | 82.467% |
| Jeil Pharma Holdings Inc | 173.03 Billion KRW | 76.687% |
| Yungjin Pharm. Co., Ltd. | 66.88 Billion KRW | 39.686% |
| Suheung Co., Ltd. | 467.85 Billion KRW | 91.378% |
| JW Pharmaceutical Corporation | 170.28 Billion KRW | 76.31% |
| Samjin Pharmaceuticals Co., Ltd. | 118.63 Billion KRW | 65.998% |
| CKD Bio Corp. | 146.92 Billion KRW | 72.545% |
| Daewon Pharmaceutical Co., Ltd. | 146.04 Billion KRW | 72.38% |
| Dongwha Pharm.Co.,Ltd | 48.25 Billion KRW | 16.405% |
| Whan In Pharm Co.,Ltd. | 632.02 Million KRW | -6282.501% |
| Shin Poong Pharm.Co.,Ltd. | 46.15 Billion KRW | 12.594% |
| Chong Kun Dang Holdings Corp. | 468.03 Billion KRW | 91.381% |
| Boryung Corporation | 204.21 Billion KRW | 80.247% |
| Bukwang Pharmaceutical Co., Ltd. | 79.38 Billion KRW | 49.187% |
| Ilyang Pharmaceutical Co.,Ltd | 85.15 Billion KRW | 52.631% |
| JW Lifescience Corporation | 46.31 Billion KRW | 12.899% |